A study testing whether a GLP-1 medicine, dulaglutide, can help people with endothelial dysfunction lower blood sugar and lose weight.
Recruiting now. Registry record last updated August 12, 2026.
- Who can join
- Adults 18 to 40, have type 1 diabetes, BMI 19+.
- What you take
- dulaglutide, given as part of the study. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 4.8 years; your own time in it is usually shorter.
- What you get
- Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
What this study is for
Primary condition: Diabetes Mellitus, Type 1. Also studied in: Endothelial Dysfunction.
Full scientific study title: Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes.
Who can join
Adults 18 to 40, have type 1 diabetes, BMI 19+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- History of type 1 diabetes, duration \> 5 years
- Age 18-40 years
- HbA1c \< 8.5%
- BMI 19-34.9 kg/m2
- Using insulin for diabetes treatment only (multiple daily injections or insulin pump with or without sensor augmentation)
Key exclusion criteria
- Pregnancy or currently breastfeeding
- Smoking history within 6 months
- History of microvascular (microalbuminuria, retinopathy, neuropathy) or macrovascular diabetes complications (coronary artery disease, stroke, peripheral vascular disease) as well as clinically significant cardiac arrhythmias or conduction disorders
- Taking vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha-blockers).
- Known hypersensitivity to perflutren (contained in Definity© contrast)
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Florida1 site
- AdventHealth Translational Research InstituteOrlando, FloridaRecruitment DepartmentCFD.TRI.Recruitment@AdventHealth.com
Timeline
Started enrolling: October 5, 2023. Expected completion: July 30, 2028. Last updated on ClinicalTrials.gov: August 12, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 17, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
